Christopher D Herzog
Overview
Explore the profile of Christopher D Herzog including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
822
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moscatelli I, Almarza E, Schambach A, Ricks D, Schulz A, Herzog C, et al.
Mol Ther Methods Clin Dev
. 2021 Feb;
20:389-397.
PMID: 33575431
Infantile malignant osteopetrosis is a devastating disorder of early childhood that is frequently fatal and for which there are only limited therapeutic options. Gene therapy utilizing autologous hematopoietic stem and...
2.
Herzog C, Bishop K, Brown L, Wilson A, Kordower J, Bartus R
Drug Deliv Transl Res
. 2015 Mar;
1(5):361-82.
PMID: 25788422
Efforts to develop neurotrophic factors to restore function and protect dying neurons in chronic neurodegenerative diseases like Alzheimer's (AD) and Parkinson's (PD) have been attempted for decades. Despite abundant data...
3.
Rafii M, Baumann T, Bakay R, Ostrove J, Siffert J, Fleisher A, et al.
Alzheimers Dement
. 2014 Jan;
10(5):571-81.
PMID: 24411134
Background: Nerve growth factor (NGF) is an endogenous neurotrophic-factor protein with the potential to restore function and to protect degenerating cholinergic neurons in Alzheimer's disease (AD), but safe and effective...
4.
Herzog C, Brown L, Kruegel B, Wilson A, Tansey M, Gage F, et al.
Neurobiol Dis
. 2013 May;
58:38-48.
PMID: 23631873
This paper reassesses the currently accepted viewpoint that targeting the terminal fields (i.e. striatum) of degenerating nigrostriatal dopamine neurons with neurotrophic factors in Parkinson's disease (PD) is sufficient for achieving...
5.
Bartus R, Baumann T, Siffert J, Herzog C, Alterman R, Boulis N, et al.
Neurology
. 2013 Apr;
80(18):1698-701.
PMID: 23576625
Objective: In an effort to account for deficiencies in axonal transport that limit the effectiveness of neurotrophic factors, this study tested the safety and feasibility, in moderately advanced Parkinson disease...
6.
Bartus R, Baumann T, Brown L, Kruegel B, Ostrove J, Herzog C
Neurobiol Aging
. 2012 Aug;
34(1):35-61.
PMID: 22926166
Neurotrophic factors have long shown promise as potential therapies for age-related neurodegenerative diseases. However, 20 years of largely disappointing clinical results have underscored the difficulties involved with safely and effectively...
7.
Bartus R, Brown L, Wilson A, Kruegel B, Siffert J, Johnson Jr E, et al.
Neurobiol Dis
. 2011 Jun;
44(1):38-52.
PMID: 21704161
Recent analyses of autopsied brains from subjects previously administered AAV2-neurturin (NRTN) gene transfer argues that optimizing the effects of neurotrophic factors in Parkinson's disease (PD) likely requires delivery to both...
8.
Bartus R, Herzog C, Chu Y, Wilson A, Brown L, Siffert J, et al.
Mov Disord
. 2011 Feb;
26(1):27-36.
PMID: 21322017
Background: AAV2-neurturin (CERE-120) is designed to deliver the neurotrophic-factor, neurturin, to the striatum to restore and protect degenerating nigrostriatal neurons in Parkinson's disease (PD). A common hypothesis is that following...
9.
Herzog C, Brown L, Gammon D, Kruegel B, Lin R, Wilson A, et al.
Neurosurgery
. 2009 Apr;
64(4):602-12.
PMID: 19349823
Objective: Parkinson's disease is characterized by profound motor deficits that result mainly as a consequence of degeneration of midbrain dopaminergic neurons. No current therapy slows or halts disease progression. Neurturin...
10.
Ramaswamy S, McBride J, Han I, Berry-Kravis E, Zhou L, Herzog C, et al.
Neurobiol Dis
. 2009 Jan;
34(1):40-50.
PMID: 19150499
Members of the GDNF family of ligands, including neurturin (NTN), have been implicated as potential therapeutic agents for Huntington's disease (HD). The present study examined the ability of CERE-120 (AAV2-NTN)...